Injective price surged over 17% as the broader crypto market moves higher, with fresh institutional and ecosystem developments adding momentum to the rally. 21Shares has filed an S-1 update for its proposed Injective ETF, outlining a potential staking allocation of 40%–60% of the fund’s INJ holdings. Meanwhile, Injective has launched on Phantom, enabling users to access and manage INJ through one of the leading wallets in the Solana ecosystem. Together, the developments strengthen the narrative surrounding institutional access and wider token utility.
21Shares Updates Injective ETF Filing With 40%–60% Staking Target
The latest ETF filing update from 21Shares introduces a staking strategy for its proposed Injective investment product. According to the disclosed details, the fund aims to stake between 40% and 60% of its INJ holdings, with the allocation adjustable based on liquidity requirements.
The proposed ETF is expected to pursue a Nasdaq listing under the ticker TINJ, while the FTSE Injective Index would serve as its pricing benchmark. BNY Mellon has been named administrator, transfer agent, and cash custodian.
The proposed staking structure could allow the fund to generate additional yield from its INJ holdings while maintaining flexibility around liquidity management. However, the filing update does not confirm regulatory approval or establish a final launch date. The development places Injective among crypto assets attracting attention through potential exchange-traded investment products. Any institutional impact will depend on the regulatory process, product approval, and eventual investor demand.
Injective Integrates With Phantom to Expand INJ Accessibility
Injective has also integrated with Phantom, enabling users to hold, trade, borrow, and exchange tokens through the wallet’s application and web extension.
The integration gives Phantom users a more direct route to interact with Injective-related assets, potentially reducing the friction associated with accessing the network’s trading and tokenization ecosystem. Phantom’s established presence across the Solana ecosystem provides Injective with an additional distribution channel beyond its native user base.
The development also supports Injective’s broader focus on financial infrastructure, cross-chain accessibility, and tokenized assets. However, wallet integration alone does not guarantee increased transaction volumes or sustained demand for INJ. Its longer-term effect will depend on actual user activity, liquidity, and the adoption of Injective-based applications.
Injective Price Analysis: INJ Rally Needs Sustained Buying Pressure
INJ’s 17% rally reflects a combination of broader market strength and renewed attention surrounding the ETF filing and Phantom integration. The sharp advance indicates improving short-term momentum, but traders should watch whether buying activity remains strong after the initial catalyst-driven move.
A continuation of the rally would require sustained volume and broader market support rather than a temporary reaction to ecosystem headlines. If momentum weakens, profit-taking could follow as short-term traders lock in gains. The ETF development and Phantom integration strengthen Injective’s narrative, but price confirmation and continued participation remain essential for a durable trend reversal.
What’s Next For Injective?
Injective’s latest developments strengthen two important parts of its market narrative: potential institutional exposure through the proposed ETF and broader accessibility through Phantom. The staking component could add another dimension to the investment product, while wallet integration may support wider ecosystem participation. Still, the long-term impact depends on regulatory progress, real user adoption, and sustained demand for INJ. The current rally reflects renewed market attention, but continued strength will require more than announcement-driven momentum.